Considering this increased risk, screening and treatment of latent tuberculosis infection (LTBI) has been recommended prior to initiation of TNF inhibitors therapy.[2,26–29] Screening for LTBI has been shown to reduce the risk of TB reactivation. The gene discussed is TNF; the disease is tuberculosis.